Wednesday, 25 February 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 25 February 2026
News

Novo's big hope fails against Lilly

Posted 24 February 2026 PM

Novo Nordisk's much hyped GLP-1/amylin combo CagriSema has been found to be less effective than Lilly's obesity shot Mounjaro, the blow sending the company's share price tumbling by more than 15 per cent.

Announcing the Phase 3 headline results from REDEFINE 4, a head-to-head trial comparing CagriSema and Mounjaro, Novo's hopeful demonstrated a 23 per cent weight loss after 84 weeks compared to 25.5 per cent for patients using Lilly's blockbuster.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.